Furthermore, our TCR recognized mutant KRAS G12V8–16, but not KRAS WT8–16 peptide, which suggests that our TCR should not recognize normal cells and potentially can be used as an “off-the-shelf” reagent for cancer immunotherapy. This evidence concerns the gene KRAS and cancer.